US Edition
Fenebrutinib curbs brain lesions in MS, Phase 2 study finds
Summary by Multiple Sclerosis News Today
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Fenebrutinib curbs brain lesions in MS, Phase 2 study finds
Fenebrutinib significantly reduced the occurrence of new brain lesions with active inflammation in people with relapsing multiple sclerosis (MS), a Phase 2 clinical trial found. In the open-label extension portion of […] The post Fenebrutinib curbs brain lesions in MS, Phase 2 study finds appeared first on Multiple Sclerosis News Today.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
